Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) Safety monitoring and information (97)
- Advertising (273)
- COVID-19 (163)
- Legislation (93)
- Compliance and enforcement (66)
- Vaping hub (53)
- Manufacturing (52)
- Labelling and packaging (35)
- Scheduling (national classification system) (27)
- Import and export (26)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
97 result(s) found, displaying 51 to 75
-
BlogAustralians who use tanning products containing ‘melanotan’ are at risk of serious health problems.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesAdditional safety information is being added to all montelukast products to strengthen and highlight existing warnings about serious neuropsychiatric events.
-
Media releasesThe defendant faces a maximum penalty of 12 months’ imprisonment and/or a fine of up to $222,000 for each charge.
-
News articlesRecall reforms program update and preview of the PRAC Version 1.0.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
BlogIf your business sells or advertises paracetamol, then you need to be aware of the new rules around pack sizes that commence on 1 February 2025.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesHealth professionals and consumers are advised that the oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be used in children under 6 years of age.
-
Safety updatesWe have received Australian reports of Guillain-Barré Syndrome (GBS) following Shingrix vaccination.
-
News articlesFrom 28 October 2024, Telstra and Optus are switching off their 3G networks. Medical devices and products like personal medical alarms could be affected by these closures.
-
News articlesSome medical device equipment could soon be affected as mobile network operators prepare to switch off their 3G networks.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
BlogOne of the key functions of the Therapeutic Goods Administration (TGA) is to closely monitor the safety of therapeutic goods. But to properly monitor safety, we need everyone to report any side effects and problems they have.
-
Safety updatesThe Product Information (PI) documents for antidepressants have been updated with warnings about sexual dysfunction continuing in some patients, after they stop using the medicines.
-
News articlesThe second phase of the Recall Reforms Program is now being implemented. Updated processes will reduce regulatory burden for sponsors while maintaining public safety.
-
Media releasesIf you use a Philips Continuous Positive Airway Pressure (CPAP) machine or a Bi-level Positive Airway Pressure (Bi-Level PAP) machine you may be affected by this recall action. Register your machine for repair or replacement to avoid any potential risks.
-
COVID-19 vaccine safety reportsIn line with the official end of the COVID-19 emergency response, this will be our last regular COVID-19 Vaccine Safety Report. We will continue safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
News articlesThe COVID-19 pandemic post-market review of facemasks is now finished.
-
Media releasesThe TGA has issued 7 infringement notices totalling $115,500 to the company for the alleged unlawful advertising and supply of sport supplement products containing banned substances.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.